Hexima News and Investor Updates

Mr Scott Robertson appointed to Board of Directors

Hexima Limited has announced the appointment of Mr Scott Robertson to its Board of Directors, effective 21 November 2018. Speaking at Hexima’s recent AGM, Chairman Professor Jonathan West said “I am pleased to announce today that we will be adding Mr Scott Robertson...

read more

Chairman and CEO update

It is our pleasure to report on an exciting year at Hexima, during which we progressed our lead drug candidate, HXP124, into first-in-human clinical trials. This is a pivotal step in the development of HXP124 as a safe and effective treatment for fungal nail...

read more

Hexima doses first patient in phase 1/2a trial of HXP124

Hexima Limited is pleased to announce today that the first patient has been dosed in its phase 1/2a clinical trial of HXP124 in patients with fungal nail infections.

Hexima’s CEO Dr Nicole van der Weerden said “Advancing HXP124 into clinical testing has been a major focus for Hexima through 2017 and we are delighted to have achieved this key milestone. This study will provide important information about the safety of HXP124 and potentially the ability of HXP124 to treat fungal nail infections and is a critical step in the development of this novel topical drug.”

Click on title to read more.

read more

Archives

Categories